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Abstract 
Long Interspersed Nuclear Elements (LINE-1) make 
up a large family of autonomous retrotransposons, 
accounting for about 17% of the human genome. 
They constitute the major source of non telomeric 
Reverse Transcriptase (RT), an essential component 
of the retrotransposition machinery. Expression of 
RT-encoding LINE-1 sequences is low in 
differentiated, non-pathological cells and highly 
active in early embryos, germ cells and in a broad 
spectrum of cancers. 
Growing evidence functionally implicate RT in 
control of cell growth and differentiation and suggest 
causative roles in cancer onset. Indeed, inhibition of 
RT activity reduces proliferation, promotes 
differentiation and antagonizes cancer progression in 
animal models. More recently, RT inhibition proved 
effective in a phase II clinical trial with metastatic 
prostate cancer patients. Furthermore, the LINE-1-
encoded ORF2p product, ecompassing the RT-
encoding sequence, was found to be already 
esxpressed in precancerous lesions, increasing in 
progressive stages, while being undetectable in 
normal tissues. RT emerges therefore as a promising 
therapeutic target and a potential marker for early 
cancer detection. At the molecular level, the 
inhibition of LINE-1-encoded RT yields a global 
reprogramming of the gene expression profile in 
cancer cells, involving all RNA classes: coding 
mRNAs, long and small non-coding transcripts, 
including miRNAs - some of which are themselevs 
key players in cancer progression, invasion, and 
metastasis. In summary, the LINE-1-encoded RT 
emerges as a key component of a genome-wide 
regulatory mechanism that is active in 
embryogenesis, repressed during cell differentiation, 
and aberrantly reactivated in cancer cells. 
Introduction 
A striking, unexpected finding from the Human 
Genome Project was that protein-coding genes 
account for a mere 1.2% of the genome, while the 
vast majority is constituted by a heterogeneous array 
of non-coding sequences (International Human 
Genome Sequencing Consortium, 2001; Waterston 
et al., 2002). That finding challenged the 
predominant "gene-centric" view in cancer research 
and represented a historical and scientific turning 
point: thereafter, the non-coding genome was no 
longer regarded as a useless genomic burden, but as 
a new component with potentially relevant 
informational content, albeit of unclear function(s). 
The findings that: i) approximately 80% of the 
genome, essentially constituted by “dark matter” 
(Clark et al., 2013), is pervasively transcribed 
(Djebali et al., 2012), and ii) a relevant fraction of 
these transcripts has roles in regulating genome 
functions, progressively strengthened the newly 
emerging view. 
Nearly 50% of the “dark matter” is constituted by 
families of retrotransposable elements. Among 
those, LINE-1 (long interspersed nuclear elements), 
HERV (human endogenous retroviruses), Alu and 
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SVA (SINE-R-VNTR-Alu; SINE, small 
interspersed nuclear elements; VNTR, variable 
number tandem repeats) are most abundant 
(reviewed by Goodier and Kazazian, 2008). These 
elements mobilize via a “copy-and-paste” 
mechanism that uses a reverse transcriptase (RT) 
 
Figure 1. LINE-1 ORF2p product is overexpressed in human cancer. A: Structure of the human LINE-1 
retroelement. 5’-UTR and 3’-UTR, untranslated regions; ORF1 and ORF2, open reading frames 1 and 2; the 
polycitronic ORF2 encompasses regions encoding EN, endonuclease (EN), reverse transcriptase (RT) and cystein-
rich (C) domains. The black box represents the intergenic spacer between the two ORFs. SP, sense promoter; ASP, 
anti-sense promoter. B: Immunohistochemical staining of ORF2p in human bioptic samples form normal and 
cancer tissues. Representative tissue sections from: normal colonic mucosa, normal prostatic gland, normal lung 
epithelium, normal breast (leftmost column) and respective carcinomas (right colum).
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enzyme to reverse-transcribe RNA intermediates 
into cDNA copies, which then integrate in several 
possible genomic sites. 
LINE-1s and HERVs encode their own RT and are 
autonomously replicating elements; in contrast, Alus 
and SVA do not code for RT and use the RT 
provided by LINE-1 for their mobilization (Levin 
and Moran, 2011). The LINE-1 family is the major 
source of the RT activity required for the overall 
retrotransposition activity in human cells (Brouha et 
al., 2003). The human genome contains about 5x105 
copies of LINE-1 sequences (Fig. 1A), comprising: 
a 5’ untranslated region (UTR) that functions as an 
internal promoter, 
two open reading frames (ORF1 and ORF2), 
separated by a short intergenic region; ORF1 codes 
for an RNA-binding protein, while ORF2 codes for 
a protein product (ORF2p) of about 150 KDa, 
endowed with endonuclese (EN) and reverse 
transcriptase (RT) activities (Alish et al., 2006); 
a short 3’ UTR. 
In the human genome, only a sub-population of 
about 80-100 LINE-1 elements maintain an intact 
full-length sequence of 6.0 kb, and are able to 
retrotranspose (Brouha et al., 2003). Most LINE-1 
copies are instead truncated copies that miss 5’ 
portions of variable length and are therefore unable 
to retrotranspose. These truncated elements, albeit 
not mobile, still maintain their transcriptional ability, 
making the ORF2-coding region the most abundant 
protein-encoding sequence compared to any other 
gene. 
.The RT-containing ORF2p product is expressed in 
cellular contexts characterized by a high 
proliferation rate and a low differentiation level, two 
conditions found in early embryos and cancer cells, 
both characterized by low levels of DNA 
methylation (Dean et al., 2003; Gaudet et al., 2003; 
Miousse and Koturbash, 2015). In contrast, 
differentiated somatic cells and tissues offer poorly 
favourable environments for LINE-1 expression (Shi 
et al., 2007), where LINE-1s are epigenetically 
suppressed or expressed only at basal level, with the 
exception of brain tissues that escape this general 
rule (Coufal et al., 2009). The functional roles of 
LINE-1 expression in embryogenesis are discussed 
elsewhere (reviewed by Sciamanna et al., 2011; 
Spadafora, 2015). Here we focus on roles of LINE-1 
retrotransposons in tumorigenesis and their 
therapeutic and diagnostic implications. 
LINE-1 activation in cancer 
A growing body of evidence now supports a direct 
correlation between LINE-1 activation and 
tumorigenesis. Concomitant with the overall 
genomic hypomethylation typical of cancer cells and 
tissues (Gaudet et al., 2003; Miousse and Koturbash, 
2015), LINE-1 function is resumed in cancer, and 
fuels bursts of retrotransposal insertions in the host 
genome, as tipically observed in the progression of a 
variety of cancers. Indeed, the development of high-
throughput technologies has enabled the 
identification and fine localization of de novo 
somatic LINE-1 insertions in the genome of many 
types of cancer, i.e.: 
 
 lung (Iskow et al., 2010), 
 colorectal (Lee et al., 2012), 
 prostate (Lee et al., 2012), 
 multiple myeloma (Lee et al., 2012), 
 glioblastoma (Lee et al., 2012), 
 hepatoma (Shukla et al., 2013), 
 esophagus (Doucet-O'Hare et al., 2015), 
 colorectal (Solyom et al., 2012), 
 pancreas (Rodic et al., 2015), 
 gastric (Ewing et al., 2015), 
 ovary (Lee et al., 2012; Tang et al., 2017). 
 
Tumors therefore provide highly permissive 
environments for retrotransposition. It has long 
remained unclear, however, whether the new 
insertions are “driver” mutations that actually 
promote tumorigenesis, or whether they are 
acompanying “passenger” mutations (Rodic and 
Burns, 2013). A causative effect of LINE-1 
insertional mutagenesis has been shown only in a 
limited number of breast (Morse et al., 1988) and 
colon cancer (Miki et al., 1992). Thus, most 
retrotransposition events appear to arise in 
consequence of a global deregulation caused by 
cancer, rather than being the causes. 
 
Nevertheless, increasing evidence indicate that high 
LINE-1 activity has roles in cancer, independent on 
the mutagenic effects of retrotranpsoisition. It is 
indeed well established that increased expression of 
LINE-1 is associated with transformed cells and 
tissues, i.e. mouse embryonal carcinoma cells 
(Martin, 1991; Martin and Branciforte, 1993) and 
testicular cancer (Bratthauer and Fanning, 1992). 
More recently, we have shown that: 
i) RT-containing ORF2p is expressed in human 
breast, lung, prostate and colon cancer tissues (Fig. 
1B), and in melanoma (A-375), glioblastoma (U-87), 
colon (HT-29), small cell lung carcinoma (H-69), 
pancreas (BxPC-3) and prostate (LnCAP, PC-3, 
DU145) carcinoma cell lines (De Luca et al., 2016); 
ii) an abundant RT enzymatic activity (Mangiacasale 
et al., 2003; Landriscina et al., 2005) is detectable in 
cancer cell lines, i.e. leukemia (NB4, R4, Kasumi-1, 
HL60), osteosarcoma (Saos-2), breast (MDA-231, 
MCF7), glioma (U-343 Mg), colon (HT-29) and 
thyroid (ARO, FRO); and 
iii) RT activity increases during breast cancer 
progression in the transgenic murine model MMTV-
PyVT (Gualtieri et al., 2013). 
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In parallel, LINE-1 ORF1p expression is a hallmark 
of colon, renal, hepatocellular, lung, breast, 
pancreatic, and biliary tract carcinomas, pediatric 
malignant germ cell and of lymphoma (Rodic et al., 
2014; Su et al., 2007). Interestingly, nuclear 
localization of ORF1p (Harris et al., 2010), or of 
both ORF1p and ORF2p (Chen et al., 2012a), was 
associated with poor prognostic outcome breast 
cancer. Finally, overexpression of LINE-1 
endonuclease domain (EN) is associated with gastric 
cancer and lymph node metastasis (Wang et al., 
2013). Together, these findings gradually shifted the 
focus away from the mutagenic potential of 
retrotranspositional genomic insertions, rather 
highlighting the importance of LINE-1 expression in 
tumorigenesis. 
LINE-1-encoded Reverse 
Transcriptase as a therapeutic 
target 
 
a) Studies in model cancer cell lines 
A functional link between LINE-1-encoded RT 
activity and cancer emerged clearly after the finding 
that RT inhibitors limit cancer cell growth. Our 
group first discovered that pharmacological 
inhibition of RT with non-nucleosidic RT inhibitors 
(NNRTi), nevirapine or efavirenz, reduces 
proliferation and promotes differentiation in a 
variety of histologically unrelated model cancer cell 
lines, i.e.: 
 osteosarcoma Saos-2 and fibrosarcoma 
L929 (Mangiacasale et al. 2003) 
 breast MCF7 (hormone-responsive) and 
MDA-231 (hormone-independent) 
carcinomas, which display very different 
sensitivty to several chemotherapics 
(Mangiacasale et al. 2003; Sciamanna et al. 
2005) 
 prostate PC3 (Sciamanna et al. 2005) 
 colon carcinoma HT-29 (Mangiacasale et 
al. 2003; Sciamanna et al. 2005) 
 small cell lung carcinoma H-69 (Sciamanna 
et al. 2005) 
 glioma U-343 Mg (Mangiacasale et al. 
2003) 
 melanoma A-375 (Sciamanna et al. 2005) 
and Me30966 (Lugini et al. 2016) cell lines 
 thyroid ARO and FRO cell lines 
(Landriscina et al. 2005 Dong et al., 2013) 
 pancreas BxPC-3 and Panc-1 cell lines 
(Hecht et al. 2013 Hecht et al. 2015) 
 cervix carcinoma HeLa (Stefanidis et al 
2008) 
 
RT inhbitors were also found to induce apoptosis in 
some leukemia cell lines, i.e. IM9, HL60 and Jurkat 
(Bruning et al. 2017). Furthermore, they promote 
differentiation, elicited by typical morphological 
variations and re-expression of specific 
differentiation markers in: 
 melanoma (A-375), upregulation E-caderin 
(Sciamanna et al. 2005), 
 prostate (PC3), upregulation PS-A antigen 
(Sciamanna et al. 2005), 
 thyroid (ARO, FRO), upregulation 
thyrotropin (TSH) receptor and thyroid 
peroxidase (TPO) (Landriscina et al. 2006; 
Modoni et al. 2007; Landriscina et al. 2008; 
Landriscina et al. 2009; Dong et al., 2013), 
 breast (MCF7, T47D, SKBR3, Hs578T, 
BT20, HBL100, and MDA-MB-231 cell 
lines), downregulation of many genes 
involved in proliferation and invasion, 
upregulation of genes involved in the 
differentiation processes (Patnala et al. 
2014). 
 
When the RT tretament was discontinued, cells 
reverted to their original condition, indicating that 
the traits induced by RT inhibitors are dependent on 
continued exposure to the treatment and are 
otherwise fully reversible (Sciamanna et al., 2005). 
RT inhibitors have no significant effect on healthy, 
non-expressing RT cells (Sciamanna et al. 2013; 
Bruning et al. 2017). 
 
b) Animal models 
Efavirenz shows anticancer therapeutic effectiveness 
in vivo in nude mouse models xenografted with 
human cell lines (Sciamanna et al., 2005): 
 melanoma A-375, 
 prostate PC3, 
 colon HT29, and 
 non small lung cell carcinoma H-69. 
 
Treatment of the xengrafted animals with efavirenz 
antagonized tumor progression, though the latter was 
resumed upon discontinuation of the treatment, 
consistent with the effects observed in cell lines. 
These results indicate that an RT-dependent tumor-
promoting mechanism plays a key role in the onset 
and progression of cancer. The mechanism is 
antagonized by RT inhibitory drugs. Finally, the 
observation that RT-dependent tumorigenesis can be 
regarded as a fully reversible process suggests an 
epigenetic level of control. 
 
Remarkably, transient (Sciamanna et al. 2005) or 
stably induced (Oricchio et al. 2007) down-
regulation of LINE-1 expression via RNA 
interference (RNAi) in A-375 melanoma cells 
reduced proliferation and promoted differentiation, 
reproducing the same effects observed with RT 
inhibitory drugs. In addition, LINE-1 silencing 
drastically reduced the tumorigenic potential of A-
375 melanoma cells inoculated in nude mice 
(Oricchio et al. 2007). These findings therefore: 
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i) suggest a causative role of LINE-1-encoded RT in 
tumorigenesis, 
ii) strengthen the finding that NNRTIs antoagonize 
cancer by specifically targeting RT, 
iii) point out that that RT is a promising target for a 
novel cancer therapy associated with re-
differentiation of the cancer cells. 
 
The anticancer efficacy of RT inhibitors has recently 
been tested in clinical therapy. A small size phase-II 
trial on patients with metastatic castration-resistant 
prostate cancer confirmed the anticancer 
effectiveness of efavirenz, assessed by PSA non-
progression, in a subgroup of patients in which the 
drug hematic concentration reached an optimal 
concentration (Houedè et al., 2014). It is worth 
stressing that heterogeneus fluctuations in the 
concentration of efavirenz in plasma of treated 
patients are a known phenomenon (Apostolova et al. 
2015, Hecht et al. 2015), and must be taken into 
account when evaluating the therapeutic efficacy of 
RT inhibitors. Case reports also confirmed the 
NNRTIs anticancer potential in HIV-negative 
patients with thyroid cancer (Landriscina et al., 
2006; Modoni et al., 2007), improved the long-term 
survival of a patient with small cell lung cancer 
(Kato et al., 2005), and showed that NNRTI-based 
HAART (highly active antiretroviral therapy) 
promoted the regression of lymphomas (Amengual 
et al., 2008; Girard et al., 2005). 
 
LINE-1-encoded RT as a 
modulator of transcriptome 
Studies addressing the RT-dependent cancer-
promoting mechanism have shown that RT 
inhibitors induce a global alteration of the 
transcription profiles, at the level of both coding and 
non-coding RNA populations: specifically, classes 
of protein-coding genes involved in proliferation, 
cell migration, and invasion become repressed 
(Sciamanna et al. 2013; Patnala et al. 2014), while 
the expression profile of non-coding sequences, 
including miRNAs and UCRs (ultraconserved long 
non-coding RNA) - which often show altered 
expression in cancer types - is deregulated to various 
extents. A link between RT activity and miRNAs 
emerged from the finding that melanoma cells 
exposed to efavirenz exhibit a reversal in the 
expression pattern of a sub-group of miRNAs, 
classified as metastamiRs, with key roles in tumor 
progression and metastasis (Sciamanna et al. 2013). 
Similarly, LINE-1 silencing in breast cancer cells 
induce differential expression of many miRNA 
species (in particular, members of the let-7 family), 
as well as few piRNAs that can potentially regulate 
gene expression (Ohms et al. 2014). A hypothetical 
mechanism for the mechanism of miRNA 
biosynthesis control by LINE-1-encoded RT has 
been recently proposed (Sciamanna et al. 2013, 
2014). In short, LINE-derived RT, overproduced in 
cancer cells, can “intercept” RNA transcripts and 
reverse-transcribe them, forming RNA:DNA hybrid 
molecules. This would be functionally equivalent to 
“sequestering” RNA strands that are rendered 
unavailable for double-stranded (ds) RNA 
formation. Consequently, production of small 
regulatory RNAs is impaired, ultimately 
compromising the expression of coding genes. 
Consistent with this, the biogenesis of LINE-1-
derived miRNAs (Lu et al., 2005) and siRNAs (Chen 
et al., 2012b) is globally reduced in cancer compared 
to normal cells. Indeed, nucleic acid fractionation 
experiments show that RT inhibitors prevent 
RNA:DNA hybrid formation (Sciamanna et al. 
2013), restoring the formation of dsRNAs and re-
establishing the biogenesis of miRNAs and their 
control of transcriptome. 
 
LINE-1-encoded Reverse 
Transcriptase as a cancer marker 
and a diagnostic tool 
The finding that LINE-1 is overexpressed in cancer 
cells, and growing preclinical and clinical data 
showing cancer responsiveness to RT inhibition, 
prompted us to undertake a systematic study to 
evaluate the expression of RT-containing LINE-1-
ORF2p in various human cancer tissues. To this end 
we have developed a highly specific monoclonal 
antibody raised against a peptide in the ORF2p EN 
domain, which enabled us to reveal by 
immunohistochemistry (IHC) LINE-1- ORF2p 
expression in bioptic tissues from staged carcinomas 
(De Luca et al., 2016). IHC analysis of prostate, 
colon, lung and breast bioptic tissues confirmed high 
ORF2p expression in carcinoma samples, but not in 
their healthy counterpart tissues (De Luca et al., 
2016). This was consistent with a previous study 
demonstrating high expression of ORF2p in breast 
cancer using an unrelated antibody (Chen et al., 
2012a). 
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Figure 2. ORF2p in progression of human cancers. A: Immunohistochemical staining of ORF2p in 
prostate cancer stages. Representative sections from: normal gland; prostatic intraepithelial neoplasia (PIN); 
adenocarcinoma with Gleason pattern 3 and 4. ORF2p signal intensities (in arbitrary units) were highly 
signficnatly different alreay in PIN compared to normal samples (details in De Luca et al., 2016). B: 
Immunohistochemical staining of ORF2p in colon cancer tissue sections. Representative sections from: normal 
colonic mucosa; transitional mucosa; adenoma with medium grade dysplasia and adenocarcinoma. ORF2p signal 
intensities (in arbitrary units) were highly signficnatly different in transitional compared to normal mucosa (see 
De Luca et al., 2016). 
 
Interestingly, high levels of ORF2p expression were 
observed in very early transformation stages in 
prostate (Fig. 2A) and colon (Fig. 2B) specimens, 
before the appearance of typical histological features 
of carcinoma, and in precancerous lesions; for 
example, transitional colonic mucosa and prostate 
intraepithelial neoplasia (PIN) showed significantly 
increased ORFp signal intensity compared to 
controls. Interestingly, parallel, independent studies 
demonstrate that genomic DNA hypomethylation 
occurs in both colonic mucosa and PIN (Suter et al., 
2004; Cho et al., 2009). 
 
In staged samples from both colon and prostate 
cancer types, ORF2p expression shows a bimodal 
pattern, with a sharp initial burst in very early stages, 
followed by a steadier wave in latest stages. It might 
be speculated that the two waves mark distinct steps 
in cancer progression: i) the normal-to-precancerous 
transition, and ii) the evolution from the latter to 
overt cancer. Aberrant activation of the LINE-1 RT 
mechanism would induce cell transformation by 
sequentially converting normal to preneoplastic and 
eventually to cancer cells through these subsequent 
steps, implicating the RT enzyme in both phases. 
The differential activation of LINE-1 RT in different 
cells might be at the origin of the heterogeneity that 
characterize tumors (rviewed by Sciamanna et al., 
2016) 
 
The finding that L1- ORF2p expression precedes 
overt tumorigenesis supports the view that high 
LINE-1 activity could be a trigger to cell 
transformation, rather than its consequence. 
Together, these data indicate that early ORF2p 
expression represents a valuable biomarker for early 
cancer detection, at least in colon and prostate 
cancer. It remains to be established whether ORF2p 
up-regulation is a more widespread phenomenon in 
other cancers at early onset. 
 
Reverse Transcriptase at the 
genesis of cancer: a model 
The data summarized thus far show that the 
activation of LINE-1-encoded RT has a cancer-
promoting role by impairing the differentiation state 
of cells, whereas RT repression restores 
LINE-1-encoded Reverse Transcriptase in the genesis and 
therapy of cancer 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2018; 22(2) 80 
 
differentiation in cancer cells with an effective 
anticancer effect. It is generally accepted that several 
cancer pathways represent the unscheduled 
resumption of early embryonic pathways that should 
have been silenced in adult differentitated cells but 
erroneously escaped that silencing. In analogy with 
cancer cells, but in a totally unrelated context, LINE-
1-encoded RT is activated at fertilization and highly 
expressed in very early embryogenesis, then 
becomes silenced in late preimplantation embryos. 
The precocious, narrow burst of RT expression is 
crucial for embryo development: indeed, both the RT 
pharmacological inhibition, and the downregulation 
of LINE-1 expression, result in arrest of embryo 
development at the 2- or 4-cell stages (reviewed by 
Sciamanna et al., 2011). 
 
By integrating these lines of evidence, RT activity 
emerges as a distinctive feature of undifferentiated, 
or poorly differentiated, cells, regardless of their 
histological origin. In tumorigenesis, a reverse 
transition occurs from differentiated back to an 
embryo-like state, accompanied by altered 
proliferation rates and morphology reflecting a 
global reprogramming of the transcriptome. 
 
Available data suggest that, in addition to the known 
role of retrotransposons in insertional mutagenesis, 
LINE-1-encoded RT plays a significant epigenetic 
role in embryogenesis and tumorigenesis by 
controlling the profile of non-coding regulatory 
RNAs. As summarized above, LINE-1-encoded RT 
operates as a master regulator of genome 
transcription, by regulating the balance between 
DNA:RNA hybrid and double-stranded RNA 
formation, and concomitantly acts as a determinant 
of cell fate. On these grounds, the elevated RT 
activity observed in virtually every type of cancer 
can cause the erroneous re-activation of embryonic 
transcriptional circuits in the wrong environment of 
adult differentiated cells (reviewed by Spadafora, 
2015). Conceptually, therefore, RT-dependent 
tumorigenesis can be regarded as the specular path 
to embryogenesis, regressing in the opposite 
direction and characterized by the re-emergence of 
embryonic features, including RT reactivation, 
genome hypomethylation and the erroneous 
resumption of genome-wide regulatory networks 
active in embryogenesis (Ma et al., 2010). 
 
LINE-1 expression is highly sensitive to stressing 
stimuli and readily modulated by them (Hagan and 
Rudin, 2002; Miousse et al., 2015). Depending on 
the nature and intensity of endogenous or exogenous 
stressors, LINE-1 expression can be activated at 
differential levels in different cells. As schematically 
represented in Fig.3, differentially intense (or 
prolonged) bursts of RT activity likely cause 
different degrees of transformation, generating the 
heterogeneity typical of cancer cells (reviewed by 
Sciamanna et al., 2016). A broad spectrum of 
transformed cells, from mildly de-differentiated 
primary cancer cells, to highly aggressive metastatic 
cells, can thus be simultaneously generated upon the 
burst of RT activity. The invasive potential of 
metastatic cells favours their spreading and make 
them the predominant population in the course of 
time. This model was inspired by the proposed “Big 
Bang”?hypothesis for the genesis of human cancer, 
in which a single?ancestral event is thought to 
originate the heterogeneity of?cancer cell 
populations (Sottoriva et al., 2015).?The model 
predicts that cell transformation is largely due to the 
reactivation of embryonic regulatory circuits, mostly 
at the epigenetic level. DNA mutations, except for 
characterized oncogenes, have lower weight in the 
genesis of cancer and would rather accumulate in 




In a critical article, Hanahan (Hanahan, 2014) has 
pointed out that the war on cancer, if not lost, is 
certainly not won yet, and has suggested that 
therapeutic strategies should stop pursuing highly 
diversified, narrow paths targeting many single 
proteins, each of which is highly selective for a 
specific cancer. Rather, effective therapeutic 
“bullets” should hit fewer targets shared by a large 
spectrum of cancers. The proposed strategy in 
Hanahan's recommendation is strikingly close to that 
inherent RT inhibitors. Indeed, based on the 
experience of our and other groups, the RT-
dependent cancer-promoting mechanism is shared 
by a variety of cancers (various carcinoma types, 
sarcoma, melanoma, and haemathological 
malignancies), suggesting that a common 
mechanism is at work in the genesis of a broad 
spectrum of histologically diverse cancers. The 
LINE-1- encoded RT, with its ability to remodel the 
profile of regulatory RNAs, would fulfill the criteria 
predicted by Hanahan, representing both the driving 
component of a newly emerging cancer-promoting 
mechanism and a worth-pursuing therapeutic target. 
In future work it remains to be seen whether RT 
inhibitors might represent “universal bullets” in a 
novel differentiation therapy, effective on an ample 
spectrum of human cancers. 
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Figure 3. A model for RT-dependent induction of cancer cell heterogeneity. The onset of deregulated 
expression of LINE-1 elements in somatic cells (green), often induced by stressing stimuli (red flash), causes a 
burst of RT activity that deregulates the transcriptome of individual cells at various levels (represented by 
different color shades): this originates heterogeneous cancer cell populations (rounded shapes). Cancer cell 
heterogeneity would thus set in following the early burst of RT activity, differentially expressed in individual 
cells. Cancer would then progress with the expansion of various cell populations (right). 
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